A Parkinson's drug that AbbVie acquired from Cerevel succeeds in another Phase 3
AbbVie once again reported positive Phase 3 data for a Parkinson’s disease drug that was acquired from its Cerevel buyout, this time as a monotherapy …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
